Great West Life Assurance Co. Can Has $921,000 Position in Anika Therapeutics Inc. (ANIK)

Great West Life Assurance Co. Can boosted its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 10.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,220 shares of the biotechnology company’s stock after buying an additional 1,974 shares during the period. Great West Life Assurance Co. Can owned 0.14% of Anika Therapeutics worth $921,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ANIK. Atria Investments LLC increased its position in shares of Anika Therapeutics by 13.9% in the first quarter. Atria Investments LLC now owns 5,563 shares of the biotechnology company’s stock worth $242,000 after buying an additional 679 shares during the period. New England Research & Management Inc. purchased a new position in shares of Anika Therapeutics during the first quarter worth approximately $447,000. Thrivent Financial for Lutherans increased its position in shares of Anika Therapeutics by 5.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,920 shares of the biotechnology company’s stock worth $388,000 after buying an additional 390 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in shares of Anika Therapeutics by 2.1% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 28,610 shares of the biotechnology company’s stock worth $1,401,000 after buying an additional 600 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in shares of Anika Therapeutics by 176.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,812 shares of the biotechnology company’s stock worth $187,000 after buying an additional 2,432 shares during the period. 81.51% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 45.32 on Friday. The company has a market cap of $664.12 million, a P/E ratio of 21.87 and a beta of 1.64. Anika Therapeutics Inc. has a 12 month low of $41.38 and a 12 month high of $54.96. The stock has a 50 day moving average of $46.47 and a 200-day moving average of $47.03.

Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.38 by $0.01. Anika Therapeutics had a return on equity of 14.29% and a net margin of 29.81%. The firm had revenue of $23.39 million during the quarter, compared to the consensus estimate of $23.89 million. During the same quarter in the previous year, the company earned $0.45 EPS. The business’s revenue was up 5.0% compared to the same quarter last year. Equities research analysts expect that Anika Therapeutics Inc. will post $1.99 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Great West Life Assurance Co. Can Has $921,000 Position in Anika Therapeutics Inc. (ANIK)” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.wkrb13.com/markets/2229583/great-west-life-assurance-co-can-has-921000-position-in-anika-therapeutics-inc-anik.html.

Separately, Zacks Investment Research downgraded shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 23rd.

In related news, Director Jeffery S. Thompson sold 10,725 shares of the stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $47.39, for a total transaction of $508,257.75. Following the completion of the transaction, the director now owns 15,845 shares in the company, valued at $750,894.55. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 5.80% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229583/great-west-life-assurance-co-can-has-921000-position-in-anika-therapeutics-inc-anik.html

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.